Valeria Cognigni - Publications

Clinically interpretable nomogram combining body composition and clinicopathological features for one year survival prediction in advanced solid tumors.

Journal: Scientific reports

Published: June 20, 2025

Feature Engineering Assessment of Tumor Infiltrating Lymphocytes in Lung Adenocarcinoma.

Journal: Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference

Published: March 05, 2025

Unraveling the link between cholesterol and immune system in cancer: From biological mechanistic insights to clinical evidence. A narrative review.

Journal: Critical reviews in oncology/hematology

Published: November 26, 2024

Molecular heterogeneity of small cell lung cancer and new therapeutic possibilities: a narrative review of the literature.

Journal: Translational lung cancer research

Published: September 14, 2024

Differential impact of lipid profile according to neutrophil-to-lymphocyte ratio status in patients with advanced cancer treated with immunotherapy.

Journal: Immunotherapy

Published: August 06, 2024

Multiple targets, germline BRCA1 mutation and HRD in a lung cancer patient: Molecular considerations and treatment decision-making.

Journal: Tumori

Published: June 13, 2024

A case series of non-small cell lung cancer patients with EGFR or HER2 exon 20 insertion in Li Fraumeni syndrome.

Journal: Tumori

Published: May 23, 2024

Successful treatment with selpercatinib after pralsetinib-related pneumonitis and intracranial failure in a patient with RET-rearranged nonsmall cell lung cancer.

Journal: Anti-cancer drugs

Published: March 07, 2024

Prognostic Impact of Blood Lipid Profile in Patients With Advanced Solid Tumors Treated With Immune Checkpoint Inhibitors: A Multicenter Cohort Study.

Journal: The oncologist

Published: March 23, 2023

The Landscape of ALK-Rearranged Non-Small Cell Lung Cancer: A Comprehensive Review of Clinicopathologic, Genomic Characteristics, and Therapeutic Perspectives.

Journal: Cancers

Published: July 27, 2022

Potential immune‑related adverse events during dabrafenib and trametinib treatment: A case series of patients with BRAF V600E melanoma.

Journal: Molecular and clinical oncology

Published: April 07, 2022

Erratum to 'Evaluation of COVID-19 impact on DELAYing diagnostic-therapeutic pathways of lung cancer patients in Italy (COVID-DELAY study): fewer cases and higher stages from a real-world scenario': [ESMO Open Volume 7, Issue 2, April 2022, 100406].

Journal: ESMO open

Published: April 04, 2022